Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Trial Profile

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs TG 6002 (Primary) ; Flucytosine
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ONCOVIRAC
  • Most Recent Events

    • 26 Oct 2017 Status changed from not yet recruiting to recruiting, according to a Transgene media release.
    • 26 Oct 2017 According to a Transgene media release, Dr. Ahmed Idbaih from La Pitie-Salpetriere hospital is the principal investigator, and first readouts of the study are expected in the second half of 2018.
    • 26 Oct 2017 According to a Transgene media release, first patient has been treated at La Pitie-Salpetriere hospital, Greater Paris University Hospitals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top